South Africa Launches Shingrix Shingles Vaccine With Potential Dementia Benefit

South Africa has launched Shingrix, a shingles vaccine that is more effective than the older Zostavax. Studies indicate Shingrix may also lower the risk of developing dementia. The vaccine requires two doses and costs nearly R5,600 (about $300), which may limit access for many South Africans. The launch follows regulatory approval and aims to protect older adults, who are most vulnerable to shingles and its complications. The potential dementia link is based on observational studies, not yet confirmed by clinical trials. Health officials have not announced any subsidy or public program to cover the cost.

Global Impact

The launch expands access to a best-in-class vaccine in a major African market, but the high price limits public health impact. If the dementia link is confirmed in ongoing trials, it could transform Shingrix from a niche adult vaccine into a cornerstone of aging population health, with massive economic implications for healthcare systems and drugmaker GSK.